Several generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.

On Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.